Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

NaV1.5-CARED NaV1.5 regulation fine-tuning as a therapy for cardiac Conduction and Arrhythmic diseases at Risk of suddEn Death

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 October 2023 to 30 September 2028
Status
Running
EU funding
€4.9m
Total cost
€4.9m
Partners
8 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101115295

What the project is doing

In the project's own words, from its summary on CORDIS.

The voltage-gated sodium channel (Na-channel; NaV1.5) is a central component of cardiac electrogenesis. Its dysfunction can lead to ventricular fibrillation and sudden cardiac death. While NaV1.5 represents a highly relevant therapeutic target for prevention of life-threatening cardiac arrhythmias, therapies that target the expression or function of this channel are non-existent. Such a therapy would provide for the first time an alternative for the invasive and costly cardioverter defibrillator or pacemaker therapies currently used.

NaV1.5-CARED consortium proposes to capitalize on their largest worldwide cohorts of patients with inherited cardiac electrical and conduction defects to uncover regulatory regions and proteins that modulate NaV1.5 expression and function with the goal to develop and validate innovative therapies to restore the function of NaV1.5. We have three objectives: 1) predict the risk of (fatal) arrhythmia and conduction defect at the individual level by developing personalized polygenic risk score (PRS), 2) characterize the molecular mechanism associating regulatory DNA regions and genes with the cardiac diseases to uncover new therapeutic targets, 3) and develop new candidates for therapeutic intervention able to restore Nav1.5 loss of function.

After databases harmonization, we will conduct whole genome genetic studies to identify variants associated with ventricular arrhythmia and conduction defects and generate PRS relevant to stratify the risk of arrhythmia and degree of conduction defect. Genetic studies will also be used to identify new therapeutic that will be evaluated in dedicated and high-throughput human cardiomyocytes derived induced pluripotent cell models.

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator
Fakultni Nemocnice U Sv Anny V BrneBrnoCzechiaParticipant
Max Delbrueck Centrum Fuer Molekulare Medizin in Der Helmholtz-Gemeinschaft (mdc)BerlinGermanyParticipant
Centre Hospitalier Universitaire De NantesNantesFranceParticipant
Nantes UniversiteNantesFranceThird party
SmartoxSaint-EgreveFranceParticipant
Pacingcure B.v.AmsterdamNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI